PCOS: Polycystic ovary syndrome

This piece is for general information and discussion only. It is not medical or legal advice.

Summary: what PCOS is and how it often shows up

Polycystic ovary syndrome is a common condition that affects hormones and how the ovaries work. Many women first notice changes to their periods, skin or hair. Some have irregular cycles, acne, hair growth in places they do not expect or thinning hair on the head. Others notice weight changes or find it harder to conceive. These symptoms do not always appear together. Some women have several; others have only one or two.

Research carried out in the UK shows that many women wait years before anyone joins the dots. Symptoms can begin in the teenage years but are often explained away as stress, puberty or “normal changes”. Many women describe seeing different professionals before they receive an explanation that makes sense.

A diagnosis does not mean continual treatment. Many women have periods of time where no active treatment is needed. Medicines are used when they are helpful for specific goals such as regulating periods, reducing androgen‑related symptoms, supporting ovulation or addressing metabolic risk. Symptoms can change across life stages.

PCOS is linked with a higher chance of insulin resistance, type 2 diabetes and some cardiovascular risk markers. These links are complicated and vary between people. Fertility can be affected mainly because of irregular ovulation rather than any issue with egg quality. Many women conceive without medical help. When support is needed, ovulation‑induction medicines are often effective.

1. Context

PCOS affects a significant proportion of women in the UK, yet it continues to be an area where many describe long waits for clarity. Investigations and research studies highlight a pattern: women often move between services, repeat their symptoms several times and encounter inconsistent explanations. Some are sent for ultrasound very early, while others struggle to access basic investigations.

PCOS sits across several parts of the NHS: primary care, gynaecology, endocrinology, dermatology, mental health and fertility services. When these services do not link well, women can receive fragmented care and mixed messages about what the condition actually means.

2. Evidence and policy

National guidance explains that PCOS is usually diagnosed by looking at a combination of three features: irregular ovulation, signs of higher androgen levels and the appearance of the ovaries on ultrasound. Guidance also stresses that imaging alone cannot confirm or rule out PCOS.

Research in the UK consistently shows links between PCOS and metabolic health. Women with PCOS are more likely to develop insulin resistance and type 2 diabetes. Studies also note higher rates of anxiety and depression, driven both by hormonal factors and by the social impact of visible symptoms. These findings vary in strength across populations but form a clear overall pattern.

HSSIB investigations, NIHR evidence reviews and other national bodies point to variation in how PCOS is assessed and explained. Differences in testing sequences, inconsistent follow‑up and reliance on ultrasound are common themes.

3. Pregnancy and the postnatal year

National maternity guidance notes that women with PCOS have a higher chance of developing gestational diabetes and some hypertensive disorders. These risks are influenced by many factors, including weight and metabolic profile. PCOS often becomes less visible during pregnancy because androgen‑related symptoms may improve.

After birth, recommended follow‑up for women who had gestational diabetes is often inconsistent. Many women with PCOS do not receive long‑term explanations about metabolic health even though evidence shows it can be helpful for future planning.

System watchpoints

This section highlights system patterns seen in research, guidance and investigations. It is not medical or legal advice, and it is not a checklist for your own care.

Who the evidence represents

Much research comes from women attending fertility clinics. This means teenagers, women not trying to conceive and women from minoritised ethnic groups may be under‑represented. This limits how well some findings apply to everyone.

Pathway fragmentation

Women commonly move between primary care, gynaecology, dermatology and fertility services. Each service may focus on one symptom rather than looking at the wider hormonal picture.

Diagnostic uncertainty

Ultrasound is sometimes used too early, despite guidance saying it should not be the only investigation. This can lead to both missed diagnoses and incorrect ones, particularly in teenagers.

Digital design

Online triage systems often filter presentations with period changes or skin concerns into low‑priority categories. This can delay review by someone who can assess hormonal conditions holistically.

Interactions with other conditions

Metabolic monitoring is not always coded or followed consistently. As women move between services, risk factors can be overlooked.

Communication and bias

Women often report being told symptoms are due to weight, stress or age without further assessment. Visible symptoms can be sensitive to discuss; poor communication can make this more difficult.

What is improving

• Updated NICE guidance encourages a broader, life‑course approach.
• Women’s health hubs aim to offer clearer and more joined‑up routes into care.
• National programmes on metabolic health are improving understanding of risk.
• Research investment is increasing, particularly on long‑term outcomes and lived experience.

Where further improvement might come from

• Better coordination between primary care, gynaecology and endocrine services.
• Clearer digital triage pathways for chronic hormonal conditions.
• Consistent coding and follow‑up of metabolic risk across services.
• More inclusive research capturing the full range of women affected by PCOS.
• Improved communication resources that reflect the varied ways PCOS presents.

Reflective questions (off‑blog)

For clinicians

  1. How consistently are hormonal, metabolic and psychological factors considered together?
  2. Do explanations acknowledge the social impact of visible symptoms?
  3. Where do delays or mixed messages most often occur locally?
  4. How are adolescent presentations distinguished from normal developmental variation?
  5. Is long‑term metabolic risk clearly coded and reviewed?

For patients (system‑level only)

  1. Were explanations about investigations easy to understand?
  2. Did you receive different messages from different services?
  3. Were metabolic health discussions offered in a timely way?
  4. How straightforward was it to move between services?
  5. Were emotional and social impacts acknowledged?

Mandatory disclaimer

This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy.

This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.

© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.

References

  1. National Institute for Health and Care Excellence. Polycystic ovary syndrome: diagnosis and management. Available at: https://www.nice.org.uk
  2. NHS England. Women’s Health Strategy for England. Available at: https://www.england.nhs.uk
  3. MBRRACE‑UK. Perinatal surveillance reports. Available at: https://www.npeu.ox.ac.uk/mbrrace-uk
  4. National Institute for Health and Care Research. PCOS evidence collections. Available at: https://evidence.nihr.ac.uk
  5. Healthcare Safety Investigation Branch / HSSIB. Investigation reports. Available at: https://www.hssib.org.uk